Journal: Frontiers in Immunology

Article Title: Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia

doi: 10.3389/fimmu.2023.1294555

Figure Lengend Snippet: Treatment of hSCF sBite-modified γδ T cells only moderately prolongs survival in vivo , despite aggressive treatment regimen. (A) Experimental design. Briefly, NSG mice were pre-conditioned with 20 mg/kg busulfan IP on day -1, then injected with 5 × 10 6 CMK cells via tail-vein injection in the morning on day 0. Beginning in the afternoon on day 0, and then once daily for the next 3 days for a total of 4 doses, 1 × 10 7 γδ T cells were injected via tail-vein injection. Mice were subjected to bioluminescence imaging for the following 3 weeks, then followed for survival until they met endpoint. n = 8 untreated, n = 6 mock T treated, n = 6 hSCF sBite treated, n = 3 mSCF CAR treated. (B) Bioluminescence images. (C) Peripheral blood leukocytes were collected 3 weeks after the start of treatment and assessed for presence of CD33 + CMK cells. Error bars represent SD. Statistical analysis represents Student’s t test (ns, p > 0.05). (D) MFI of c-kit on CMK cells within the periphery. Statistical analysis represents Student’s t test (ns, p > 0.05). (E) Kaplan-Meier survival analysis. Untreated and mock γδ T treated groups were combined as a control group. Statistical analysis represents log rank (Mantel-Cox) test (ns > 0.05). P-value is shown. (F) Representative flow plots of hCD33 + hCD45 + CMK cells in the bone marrow of an untreated mouse sacrificed near end-point.

Article Snippet: Bioluminescence was quantified using Living Image Software (PerkinElmer, Waltham, MA, USA) or Aura Software (Spectral Instruments Imaging, Tucson, AZ, USA).

Techniques: Modification, In Vivo, Injection, Imaging, Control